MMP9 and androgen insensitivity syndrome: To explore the potential plasma markers that could be used to predict the AIS outcome after IVT, we prospectively collected peripheral blood from AIS patients before and after IVT to investigate the following plasma biomarkers, interleukin-6 (IL-6), matrix metalloproteinase 9 (MMP-9), a disintegrin and metalloproteinase with a thrombospondin type 1 motif member 13 (ADAMTS13), tenascin-C(TNC), gelsolin(GSN), and thioredoxin (TRX).